Curcumin-piperine co-supplementation significantly reduces weakness in COVID-19 patients

Salient findings of the study include:

· Mean changes in complete blood count, liver enzymes, blood glucose levels, lipid parameters, kidney function, and c-reactive protein (CRP) were not significantly different between the two groups.

· There was a significant improvement in health status, including dry cough, sputum cough, ague, sore throat, weakness, muscular pain, headache, and dyspnea at week 2 in both curcumin-piperine and placebo groups; however, the improvement in weakness was more in the curcumin-piperine group than with placebo group.

"In outpatients with COVID-19, curcumin-piperine co-supplementation can significantly reduce weakness," wrote the authors. "However, in this study, it did not significantly affect the other indices, including biochemical and clinical indices."

"In the future, more clinical trials with larger sample size and higher dose and duration will be required to ascertain curcumin use as an adjunct therapy in COVID-19 patients," they concluded.

Reference:

Askari, G., Sahebkar, A., Soleimani, D. et al. The efficacy of curcumin-piperine co-supplementation on clinical symptoms, duration, severity, and inflammatory factors in COVID-19 outpatients: a randomized double-blind, placebo-controlled trial. Trials 23, 472 (2022). https://doi.org/10.1186/s13063-022-06375-w